secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2025-10-24T23:59:59+00:00
Accession:  0001213900-25-101825
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 1.02, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oramed terminates HTIT joint venture, repurchases 1.15M shares, reports ~$210M in assets, launches new insulin trial
--------------------------------------------------------------------------------

- Repurchased 1,155,367 shares from HTIT Biotech at $2.23/share for $2.58M total; shares cancelled.
- Terminated joint venture with HTIT after it failed to satisfy closing conditions; oral insulin program to continue independently.
- Preliminary unaudited cash and assets ~$210M as of Sep 30, 2025, up from $155.7M in Jan 2023.
- Initiating 60-patient US oral insulin trial targeting high-responder subgroups (lower BMI, older) for >1% HbA1c reduction.
- Investment portfolio: $27.1M unrealized gain on Alpha Tau ($64.8M position); Scilex loan returned $95.5M of $99.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390025101825/0001213900-25-101825-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390025101825/ea0262319-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-101825

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer